Skip to main content
Premium Trial:

Request an Annual Quote

New Molecular Dx Player Helixis Raises $10M in Series A Funding

Helixis, a newly formed molecular diagnostics firm based in Carlsbad, Calif., announced this week that it has raised $10 million in a Series A round of funding.
The firm was co-founded by Alex Dickinson, a former CEO of Luxtera who serves as Helixis’ CEO; David Baltimore, president emeritus and Robert Andrews Millikan professor of biology at the California Institute of Technology; and Axel Scherer, professor of electrical engineering, applied physics and physics at Caltech.
Helixis’ intellectual property portfolio is exclusively licensed from Caltech and comprises more than 40 patents and patent filings.
“We’ve developed a new generation of molecular diagnostic technology that radically reduces cost, size, and power requirements without compromising efficacy,” Dickinson said in a statement.
The firm did not provide specifics on its technology or how it offers these advantages over current molecular diagnostic technologies.
The funding was led by venture capitalists Jim Blair of Domain Associates and Sharon Stevenson of Okapi Venture Capital.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.